Evidence map›Paper›PMID 40897818›Full record

ArticleBritish journal of cancer2025

Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma.

Kuntal Halder, Erkut H Borazanci, Gayle S Jameson, Wei Lin, Amber Vrana, Derek Cridebring, Susan Tsai, Mohammed Aldakkak, Douglas B Evans, Masamichi Hayashi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kuntal HalderClinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Part of City of Hope, Phoenix, AZ, USA.
Erkut H BorazanciHonorHealth Research Institute, Scottsdale, AZ, USA.
Gayle S JamesonHonorHealth Research Institute, Scottsdale, AZ, USA.
Wei LinClinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Part of City of Hope, Phoenix, AZ, USA.
Amber VranaHonorHealth Research Institute, Scottsdale, AZ, USA.
Derek CridebringClinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Part of City of Hope, Phoenix, AZ, USA.
Susan TsaiDepartment of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA.
Mohammed AldakkakDepartment of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA.
Douglas B EvansDepartment of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA.
Masamichi HayashiDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Haruyoshi TanakaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mitsuro KandaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ajay GoelDepartment of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-1396-6341
Daniel D Von HoffClinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Part of City of Hope, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0003-4723-7681
Haiyong HanClinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Part of City of Hope, Phoenix, AZ, USA. hhan@tgen.org.ORCID http://orcid.org/0000-0001-9031-9880

Funding

Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic CancerU01CA214254 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Ajay Goel, DANIEL D VON HOFF · 2017 to 2026
$8.9M
NCI NIH HHS U01 CA214254U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA214254
6 · The paper itself

Abstract

backgroundLack of reliable biomarkers for early detection and monitoring contributes to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC), as the current clinical marker, CA19-9, lacks adequate specificity and sensitivity.

methodsSerum concentrations of ALPPL2-positive and THBS2-positive exosomes were measured using an ExoView assay in two cohorts: a cohort of 219 subjects, including non-disease controls and patients with early- or late-stage PDAC, and a longitudinal cohort of 26 patients with advanced PDAC undergoing treatment.

resultsExosomal ALPPL2 and THBS2 distinguished non-cancer cases from PDAC with high accuracy; area under the curve (AUC) values = 0.983, 0.993, and 0.983 for ALPPL2, THBS2, and the dual marker combination, respectively. Additionally, changes in the concentrations of ALPPL2

conclusionsSerum exosomal ALPPL2 and THBS2 can accurately discriminate patients with PDAC from individuals with non-cancerous conditions and healthy controls. Changes in serum exosomal ALPPL2 and THBS2 levels significantly correlate with patients' response to treatment in both CA19-9-elevated and non-elevated patients.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalExosomesPancreatic NeoplasmsThrombospondinsAdultAgedCase-Control StudiesEarly Detection of CancerFemaleHumansMaleMiddle AgedPrognosisThrombospondin 2Biomarkers, TumorThrombospondin 2Thrombospondins

Identifiers

PMID40897818
PMCPMC12572646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.